Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$55.53 USD
-0.32 (-0.57%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $55.43 -0.10 (-0.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cytokinetics (CYTK) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$82.76 | $107.00 | $60.00 | 48.18% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Cytokinetics comes to $82.76. The forecasts range from a low of $60.00 to a high of $107.00. The average price target represents an increase of 48.18% from the last closing price of $55.85.
Analyst Price Targets (17)
Broker Rating
Cytokinetics currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 11.11% of all recommendations. A month ago, Strong Buy made up 72.22%, while Buy represented 11.11%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CYTK.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 13 | 13 | 13 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 4 | 4 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.56 | 1.44 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Goldman Sachs | Paul K Choi | Strong Buy | Hold |
8/12/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
8/12/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
8/12/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
8/9/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
8/8/2024 | SVB Securities | Roanna Ruiz | Strong Buy | Strong Buy |
8/8/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/8/2024 | Raymond James | Sean Mccutcheon | Moderate Buy | Moderate Buy |
6/9/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
5/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
3/6/2024 | Mizuho SecuritiesUSA | Salim Syed | Strong Buy | Strong Buy |
3/4/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/24/2024 | UBS | Ashwani Verma | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 18 |
Average Target Price | $82.76 |
LT Growth Rate | 18.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -1.25 |